DUSA Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

DUSA 0.0000
price chart
DUSA Pharmaceuticals Is A Small Gem
DUSA Pharmaceuticals, Inc. (DUSA), a vertically integrated dermatology company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions primarily in the United States, Canada, and Korea.
Shedding A Little Light On Under-Followed DUSA Pharmaceuticals
Originally DUSA had an agreement with Schering to sell the therapy, but initial sales were poor because of reimbursement issues and DUSA ultimately had to take it over for themselves. With the capital limitations of a small, money-losing company, DUSA ...
Related articles »  
DUSA Pharmaceuticals Shares Tumble After Earnings: Low Growth Ahead?
DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA) - based in Wilmington, MA is a dermatology company engaged in the development and commercialization of Levulan photodynamic therapy (PDT).
Related articles »  
Caraco Pharmaceutical Laboratories and DUSA Pharmaceuticals Announce ...
DETROIT and WILMINGTON, Mass., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Caraco Pharmaceutical Laboratories, Ltd. ("CPL"), a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), and DUSA Pharmaceuticals, Inc.
Related articles »  
Ryan & Maniskas, LLP Announces Investigation of DUSA Pharmaceuticals Inc.
WAYNE, Pa.--(BUSINESS WIRE)--Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/dusa) is investigating potential claims against the board of directors of DUSA Pharmaceuticals Inc. (�DUSA� or the �Company�) (NASDAQ: DUSA) for potential breaches of ...
Related articles »  
Sun Pharma inks pact to buy DUSA for $230 million
Sun Pharma and DUSA Pharmaceuticals have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photo-dynamic therapy platform, Sun Pharma said in a ...
Sun Pharma to buy Dusa for $230 million  Livemint
Sun Pharma to pay $230 m for US dermatology firm DUSA  Hindu Business Line
Related articles »  
DUSA: A Pharmaceutical With Profits Now and Strong Growth Ahead
Newly profitable small-cap biotechnology company DUSA Pharmaceuticals (NASDAQ:DUSA) is an investment with fantastic return opportunities.
Related articles »  
DUSA Pharmaceuticals Reports Notice of Allowance for Key PDT Device Patent
WILMINGTON, Mass., May 7 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.� (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan� Photodynamic Therapy (PDT), today announced that the United States Patent ...
Related articles »  
Caraco Pharmaceutical Laboratories Announces Successful Tender Offer To ...
... tender offer by Caraco Acquisition Corporation, a wholly-owned subsidiary of CPL, to acquire all of the outstanding shares of common stock of DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) ("DUSA") for $8.00 per share, net to the seller thereof in ...
Takeda to sell generics biz from URL deal  The Deal Pipeline
Sun Pharma rises 3% on acquisition of US firm URL Pharma  Firstpost
Related articles »  
Caliber Imaging & Diagnostics Names Richard C. Christopher to Chief Financial ...
Mr. Christopher served for eight years as Chief Financial Officer of DUSA Pharmaceuticals, Inc., until its sale to Sun Pharmaceuticals Industries Limited in 2012.
Related articles »